Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Rheumatology

Survivorship and Long-Term Monitoring: Life After Diagnosis

At a Glance

Long-term management of immune-mediated necrotizing myopathy (IMNM) requires knowing your specific antibody subtype and maintaining a stable Creatine Kinase (CK) baseline. Engaging in physical therapy and attending regular heart, lung, and cancer screenings are crucial for preventing relapses.

The transition from initial diagnosis to long-term management—often called survivorship—is a shift from “putting out the fire” to rebuilding your strength and preventing the fire from returning. While Immune-Mediated Necrotizing Myopathy (IMNM) is a chronic condition, many patients achieve stable remission with the right monitoring and rehabilitation plan [1][2].

Long-Term Monitoring: The “Watchlist”

Your monitoring schedule is dictated largely by your specific biological subtype, as each carries different long-term risks [3].

  • Heart and Lungs: Because IMNM can affect the heart (cardiomyopathy or arrhythmias) and the lungs, regular check-ups are essential [4][5]. This is especially critical for the anti-SRP subtype, where heart involvement can be “silent” but severe [6][7]. Expect periodic EKGs, echocardiograms, and Pulmonary Function Tests (PFTs) [5][8].
  • Recurring Cancer Checks: While the most intense cancer screening occurs during your initial diagnosis (especially for seronegative patients), your doctor will likely recommend continuing age-appropriate and thorough cancer screenings periodically to ensure no malignancy develops [9][10].
  • The CK “Baseline”: Once your disease is under control, your Creatine Kinase (CK) level should stabilize. Knowing this “remission number” is vital; if your CK begins to rise again, it is often the first sign of a relapse before you even feel new weakness [11][12].

Physical Therapy and Structural Rehabilitation

Rebuilding muscle after a necrotizing attack is different from normal bodybuilding. Because the immune system has physically destroyed fibers, you need structural rehabilitation [13].

  • Exercise is Safe: A common myth is that exercise will “break down” more muscle in IMNM patients. In fact, research shows that structured endurance and resistance training is not only safe but essential for recovery [14][15].
  • PT Goals: A physical therapist (PT) can help you focus on proximal strength—the hips and shoulders—using tools like gait training or robotics to help you regain your mobility [13][14].

Recognizing a Relapse

A relapse occurs when the immune system “wakes up” and begins attacking the muscles again. You should contact your medical team immediately if you notice these “red flags” [16][12]:

  • New Muscle Pain (Myalgia): Especially common in seronegative patients [17].
  • Difficulty Lifting Your Head: This is a sign of neck muscle weakness, often an early warning sign of a flare [18].
  • New Fatigue: Feeling exhausted by simple tasks that were easy just a week ago [18].

Outlook by Subtype

While every journey is unique, the research offers some general trends for long-term prognosis [3][19]:

  • Seronegative: Generally has the most favorable long-term outcomes, provided initial and ongoing cancer checks remain clear [17].
  • Anti-HMGCR: Often requires long-term, intensive therapy (like IVIG) to stay in remission but can achieve significant strength gains [20][21].
  • Anti-SRP: Often the most “stubborn” to treat and requires the most vigilant monitoring of the heart and lungs, but early use of rituximab has significantly improved the outlook for these patients [22][23].

Survivorship Checklist

  • [ ] Baseline Vitals: Do you have a recent EKG and Pulmonary Function Test on file? [5]
  • [ ] Cancer Check: Is your cancer screening up to date for your age and subtype? [9]
  • [ ] PT Plan: Are you working with a physical therapist to rebuild “structural” muscle? [14]
  • [ ] Relapse Plan: Do you know which number to call if you feel new weakness or your CK rises? [16]

Common questions in this guide

What are the early warning signs of an IMNM relapse?
Early signs of an IMNM relapse include new muscle pain (myalgia), difficulty lifting your head from a pillow, and sudden, severe fatigue. Additionally, a rising Creatine Kinase (CK) level on your blood tests can indicate a relapse before physical symptoms appear.
Is it safe to exercise if I have immune-mediated necrotizing myopathy?
Yes, exercise is generally safe and highly recommended for IMNM recovery. Structured endurance and resistance training, guided by a physical therapist, is essential to help rebuild muscle fibers that were damaged by your immune system.
Why do I need heart and lung tests if IMNM only affects my muscles?
IMNM can sometimes involve the heart muscle and the lungs, particularly in patients with the anti-SRP subtype. Regular echocardiograms, EKGs, and pulmonary function tests are necessary to detect and treat any organ involvement as early as possible.
How does my IMNM subtype affect my long-term prognosis?
Your specific antibody subtype directly influences your monitoring schedule and long-term treatment plan. For example, anti-SRP patients require more vigilant heart monitoring, while seronegative patients generally have favorable outcomes if cancer screenings remain clear.
How often do I need cancer screenings after my IMNM diagnosis?
While the most intensive cancer screening happens at your initial diagnosis, periodic age-appropriate checkups are still necessary to ensure no malignancy develops over time. Your doctor will tailor this screening schedule to your specific subtype and age.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my subtype, what is the recommended schedule for my routine cancer screenings (CT, PET, or age-appropriate screens)?
  2. 2.Do I need a baseline echocardiogram and EKG, and how often should we repeat these to monitor my heart?
  3. 3.What is our long-term plan for tapering my steroids while ensuring I don't relapse?
  4. 4.Can you provide a referral for a physical therapist who has experience with inflammatory myopathies?
  5. 5.What CK number should I consider a 'red flag' that requires an immediate call to your office?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Statin-Associated Autoimmune Myopathy: Review of the Literature.

    Barrons R

    Journal of pharmacy practice 2023; (36(2)):383-393 doi:10.1177/08971900211040291.

    PMID: 35707933
  2. 2

    Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.

    Vaezi Z, Amini A

    Cureus 2025; (17(11)):e97933 doi:10.7759/cureus.97933.

    PMID: 41458822
  3. 3

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  4. 4

    Necrotizing myopathy presenting as congestive heart failure and life-threatening ventricular arrhythmias: a case report.

    Lim K, Park JS, Yoon BA, Han SH

    European heart journal. Case reports 2021; (5(6)):ytab075 doi:10.1093/ehjcr/ytab075.

    PMID: 34142007
  5. 5

    Cardiac and Respiratory Complications of Necrotizing Autoimmune Myopathy.

    Triplett J, Kassardjian CD, Liewluck T, et al.

    Mayo Clinic proceedings 2020; (95(10)):2144-2149 doi:10.1016/j.mayocp.2020.03.032.

    PMID: 32807522
  6. 6

    Predictors of cardiac involvement in idiopathic inflammatory myopathies.

    Bandeira M, Dourado E, Melo AT, et al.

    Frontiers in immunology 2023; (14()):1146817 doi:10.3389/fimmu.2023.1146817.

    PMID: 36969246
  7. 7

    Anti-SRP Antibodies and Myocarditis in Systemic Sclerosis Overlap Syndrome with Immune-Mediated Necrotizing Myositis (IMNM).

    Alexandru C, Donisa A, Bobirca F, et al.

    Medicina (Kaunas, Lithuania) 2024; (60(11)) doi:10.3390/medicina60111756.

    PMID: 39596941
  8. 8

    Severe Anti-HMG-CoAR Necrotizing Autoimmune Myopathy Secondary to Statin Use.

    Pulipati P, Reddy JK, Husain SA

    Case reports in rheumatology 2022; (2022()):6120424 doi:10.1155/2022/6120424.

    PMID: 36158465
  9. 9

    Paraneoplastic anti-SRP antibody positive immune-mediated necrotizing myopathy in a young female associated with lymphoma.

    Heugenhauser J, Pauli FD, Stockhammer G, et al.

    Journal of neuromuscular diseases 2025; (12(4)):567-574 doi:10.1177/22143602251327002.

    PMID: 40266663
  10. 10

    A case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive paraneoplastic necrotizing myopathy associated with advanced gastric cancer that responded to intravenous immunoglobulin therapy.

    Yamaguchi T, Matsunaga A, Ikawa M, et al.

    Rinsho shinkeigaku = Clinical neurology 2017; (57(3)):118-123 doi:10.5692/clinicalneurol.cn-000982.

    PMID: 28228619
  11. 11

    A case of asymptomatic hyperCKemia for 40 years leading to a diagnosis of treatable immune-mediated necrotizing myopathy.

    Ishida R, Eura N, Nishimori Y, et al.

    Neuromuscular disorders : NMD 2025; (56-57()):106215 doi:10.1016/j.nmd.2025.106215.

    PMID: 41138436
  12. 12

    Statin-induced necrotizing autoimmune myopathy: An uncommon complication of a commonly used medication.

    Saleh Y, Herzallah K, Hassanein M, Chang HT

    Journal of the Saudi Heart Association 2019; (31(4)):269-272 doi:10.1016/j.jsha.2019.08.001.

    PMID: 31516306
  13. 13

    INPATIENT REHABILITATION AND FUNCTIONAL OUTCOME OF A CASE OF ANTI-SRP IMMUNE-MEDIATED NECROTIZING MYOPATHY.

    Chen N, Yamin Thein K, San Tay S

    Journal of rehabilitation medicine. Clinical communications 2024; (7()):40653 doi:10.2340/jrm-cc.v7.40653.

    PMID: 39444782
  14. 14

    Physical therapy in adult inflammatory myopathy patients: a systematic review.

    Van Thillo A, Vulsteke JB, Van Assche D, et al.

    Clinical rheumatology 2019; (38(8)):2039-2051 doi:10.1007/s10067-019-04571-9.

    PMID: 31115788
  15. 15

    Epidemiology of Dermatomyositis and Other Idiopathic Inflammatory Myopathies in Northern Spain.

    Corrales-Selaya C, Prieto-Peña D, Martínez-López D, et al.

    Biomedicines 2025; (13(10)) doi:10.3390/biomedicines13102537.

    PMID: 41153817
  16. 16

    When Statins Get Physical: A Curious Cause of Statin Myopathy.

    Patel PP, Jackson CD

    Southern medical journal 2022; (115(4)):266-269 doi:10.14423/SMJ.0000000000001379.

    PMID: 35365843
  17. 17

    The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China.

    Ma X, Xu L, Ji S, et al.

    Frontiers in neurology 2021; (12()):670784 doi:10.3389/fneur.2021.670784.

    PMID: 34290662
  18. 18

    Identical twins with statin-associated anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibody-positive autoimmune myopathy.

    Mali M, Pirilä L, Perander L, et al.

    Scandinavian journal of rheumatology 2024; (53(1)):81-82 doi:10.1080/03009742.2023.2289729.

    PMID: 38090763
  19. 19

    Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical-serological-pathological classification.

    Yang H, Zhang L, Tian X, et al.

    Rheumatology (Oxford, England) 2025; (64(4)):2252-2264 doi:10.1093/rheumatology/keae361.

    PMID: 39029922
  20. 20

    Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

    Anquetil C, Boyer O, Wesner N, et al.

    Autoimmunity reviews 2019; (18(3)):223-230 doi:10.1016/j.autrev.2018.09.008.

    PMID: 30639649
  21. 21

    Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins.

    Khan F, Brady S, Kuttikat A

    Rheumatology international 2023; (43(2)):383-390 doi:10.1007/s00296-022-05230-0.

    PMID: 36260115
  22. 22

    Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.

    Watanabe Y, Uruha A, Suzuki S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2016; (87(10)):1038-44 doi:10.1136/jnnp-2016-313166.

    PMID: 27147697
  23. 23

    A Case of Acute Necrotizing Myopathy in a Patient with Systemic Lupus Erythematosus.

    Jackson N, Babalola T, Betty S, et al.

    The American journal of case reports 2022; (23()):e932867 doi:10.12659/AJCR.932867.

    PMID: 35082254

This page provides educational information on IMNM survivorship and long-term monitoring. Always consult your neurologist or rheumatologist before changing your physical therapy routine or treatment plan.

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.